TABLE 2.
Target gene | Primer sequence (5′–3′) |
|
---|---|---|
Forward | Reverse | |
ACE2 human | GGACCCAGGAAATGTTCAGA | GGCTGCAGAAAGTGACATGA |
ACE2 FLG | TGGGACTCTACCGTTCACTTA | GCTTCATCTCCCACCACTTT |
ACE2 Mm | TGCTTATGTCAGGGCAAAGT | CCCACATATCACCAAGCAAATG |
ACE2 Nn | CAGTCCTGGGATGCAGATAAG | TGGCTCAGTTAGCATGGATTTA |
GAPDH human | GGTCGGAGTCAACGGATTTG | ACTCCACGACGTACTCAGCG |
GAPDH FLG | TCATCAACGGAAAGTCCATCTC | ACATACTCAGCACCAGCATC |
GAPDH Mm | GTAGTGAAGCAGGCATCAGAG | GGAGTGGGTGTCACTGTTAAA |
GAPDH Nn | CCTGTTCGTCAGACAGCCTT | TTGATGGCGACAACTTGCAC |
IFIH1 human | ACA CGT TCT TTG CGA TTT CC | ACC AAA TAC AGG AGC CAT GC |
IFIH1 Mm/FLG | GGAGTCAAAGCCCACCATCT | TCCAGACCTTCTTCTGCCAC |
IFIH1 Nn | TTTGCCAAGTGAGCCCAATG | AAGCGGTCTTTGCGATTTCC |
OAS human | GAGCTCCTGACGGTCTATGC | TTCGTGAGCTGCCTTCTCAG |
OAS pan-bat | GGAAGGAGGGCGAGTTCTC | GGTACCAGTGCTTGACCAGG |
SARS-CoV-2 nsp12 polymerase | GGTAACTGGTATGATTTC | CTGGTCAAGGTTAATATAGG |